3200 Rare Diseases: Now Who Is Going to Cure Them?

To the patients who benefit from treatments that may have otherwise never been developed, your contribution would mean everything.
Gene Therapies: Justifiably Expensive or a Mirage of Cost Effectiveness

An exploration of value based pricing, how willingness-to-pay and ´novel concepts are inflating the cost effectiveness of gene therapies.
Crowdfunding for a Cure

Crowdfunding is a growing democratic alternative to venture capital. Can it also provide the fuel to accelerate novel therapies for those left behind by for profit healthcare…
Defying Eroom’s Law

Economic challenges in rare disease gene therapy, intensified by Eroom’s law, demand innovative solutions. Amid accusations of pharmaceutical oligopoly and economic inequality, potential remedies lie in collaborative, decentralized business models.